Nilvadipine

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Nilvadipine
Nilvadipine structure.svg
Clinical data
AHFS/Drugs.com International Drug Names
ATC code
Identifiers
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
ECHA InfoCard 100.232.871
Chemical and physical data
Formula C19H19N3O6
Molar mass 385.370 g/mol
3D model (JSmol)
 NYesY (what is this?)  (verify)

Nilvadipine is a calcium channel blocker (CCB) used for the treatment of hypertension and chronic major cerebral artery occlusion.

Pathohistochemical studies have revealed that the volume of the infarction in the middle cerebral artery occlusion model could be decreased by nilvadipine.

Nilvadipine was tested in clinical trial as a possible treatment for Alzheimer's Disease in Ireland by the Roskamp Institute, Florida, USA and Trinity College, Ireland.[1]

Following this study, an international research consortium led by Trinity College Dublin (Ireland) in May 2011 announced the selection for funding of a large-scale European clinical trial of nilvadipine. More than 500 Alzheimer’s patients will participate in the multicenter phase III clinical trial designed to study the effectiveness of nilvadipine.[2]

References[edit]